Abstract | PURPOSE: PATIENTS: Data were retrospectively analyzed for 350 patients registered in the German Neuroblastoma trials NB97 and NB04 who were treated with high-risk protocols-including myeloablative chemotherapy with autologous stem cell transplantation (SCT) or maintenance therapy-and had received 13-cisRA between January 1, 2000 and December 31, 2010. RESULTS:
Hypercalcemia was reported in 78 patients (22.3%), and 37 patients (10.6%) developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 hypercalcemia. The calcium levels were 2.5-4.6 mmol/L (median 3.1 mmol/L). Patients with a single kidney were at a higher risk of developing hypercalcemia (p = .001). Regarding postinduction treatment, 69 of 280 patients with SCT (24.6%) and nine of 70 patients without SCT (12.9%) developed hypercalcemia during 13-cisRA treatment (p = .037). Most patients developed hypercalcemia in the first cycle of 13-cisRA, and only in a single cycle. Hypercalcemia symptoms were frequent but moderate. In most patients, treatment with 13-cisRA was continued without dose reduction in subsequent cycles. CONCLUSION:
|
Authors | Marc Hoemberg, Ruth Schwenzfeur, Frank Berthold, Thorsten Simon, Barbara Hero |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 69
Issue 2
Pg. e29374
(02 2022)
ISSN: 1545-5017 [Electronic] United States |
PMID | 34569150
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC. |
Chemical References |
|
Topics |
- Drug-Related Side Effects and Adverse Reactions
(drug therapy)
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Hypercalcemia
(chemically induced)
- Isotretinoin
(adverse effects)
- Male
- Neuroblastoma
(drug therapy)
- Retrospective Studies
- Solitary Kidney
(drug therapy)
- Transplantation, Autologous
|